G
The U. S. Food and Drug Administration, Center for Biologics Evaluation and Research (CBER), Office of Division of Plasma Protein Therapeutics’ (DPPT) / Hemostasis Branch (HB) require services to determine a reliable and comprehensive identification of the FVIII-derived peptides to determine if there are differences between wild-type and codon optimized proteins in the way they are processed by antigen presenting cells.